Fig. 3.
Disease-free survival curves for patients undergoing bone marrow transplantation.
(A) Disease-free survival (DFS) for patients receiving an allogenic transplant. Group 1, daunorubicin; group 2A, 10 mg/m2idarubicin; group 2B, 12 mg/m2 idarubicin. (B) DFS for patients receiving an autologous transplant. (C) DFS for patients receiving an autologous transplant comparing melphalan (Mel) conditioning with busulphan and cyclophosphamide (BU/CY). Group 1, daunorubicin; group 2, all idarubicin patients.
